The trading price of Day One Biopharmaceuticals Inc (NASDAQ:DAWN) closed lower on Monday, November 18, and closing at $13.01, -2.25% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $12.8631 and $13.6681. In examining the 52-week price action we see that the stock hit a 52-week high of $18.07 and a 52-week low of $11.30. Over the past month, the stock has lost -13.32% in value.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Day One Biopharmaceuticals Inc, whose market valuation is $1.22 billion at the time of this writing, is expected to release its quarterly earnings report in December. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -0.48 per share this quarter, however they have predicted annual earnings per share of -0.81 for current year and -1.12 for next year.
Analysts have forecast the company to bring in revenue of 27.15M for the current quarter, with the likely lows of 23.97M and highs of 32M. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 114.59M.
On the technical side, indicators suggest DAWN has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned DAWN a recommendation rating is 5. Out of them, 0 rate it a Hold, while 5 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Day One Biopharmaceuticals Inc (DAWN) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that DAWN’s price is currently -11.81% off the SMA20 and -9.65% off the SMA50. The RSI metric on the 14-day chart is currently showing 33.41, and weekly volatility stands at 6.10%. When measured over the past 30 days, the indicator reaches 5.54%. Day One Biopharmaceuticals Inc (NASDAQ:DAWN)’s beta value is currently sitting at -1.54, while the Average True Range indicator is currently displaying 0.80. With analysts defining $24-$45 as the low and high price targets, we arrive at a consensus price target of $40 for the trailing 12-month period. The current price is about -84.47% off the estimated low and -245.89% off the forecast high, based on this estimate. Investors will be thrilled if DAWN’s share price rises to $40, which is the median consensus price. At that level, DAWN’s share price would be -207.46% below current price.
To see how Day One Biopharmaceuticals Inc stock has been performing in comparison to its peers in the industry, here are the numbers: DAWN stock’s performance was -2.25% in the latest trading, and 11.01% in the past year.
An evaluation of the daily trading volume of Day One Biopharmaceuticals Inc (NASDAQ:DAWN) indicates that the 3-month average is 1.05 million. However, this figure has increased over the past 10 days to an average of 1.42.
Currently, records show that 87.23 million of the company’s shares remain outstanding. The insiders hold 32.14% of outstanding shares, whereas institutions hold 81.55%. The stats also highlight that short interest as of 2024-10-31, stood at 18.02 million shares, resulting in a short ratio of 15.57 at that time. From this, we can conclude that short interest is 2159.00 of the company’s total outstanding shares. It is noteworthy that short shares in October were up slightly from the previous month’s figure, which was 15.67 million. However, since the stock’s price has seen -10.89% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
